Clinical benefits of transarterial chemoembolization combined with tyrosine kinase and immune checkpoint inhibitors for unresectable hepatocellular carcinoma

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 7

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

HTML

484

Figures (1-4)

125

Tables (1-2)

Sum=738

Publishing Process of This Article

Item

Count

Browse

Download

Sum=119

Jul 15, 2024 (publication date) through Nov 16, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Meta-Analysis

World J Gastrointest Oncol. Jul 15, 2024; 16(7): 3308-3320
Published online Jul 15, 2024. doi: 10.4251/wjgo.v16.i7.3308

Full Size Figure Download Figure

Figure 4 Forest plots of adverse events. A: The pooled rate of all-grade adverse events (AEs); B: The pooled rate of grade ≥ 3 AEs.

Citation: Han F, Wang XH, Xu CZ. Clinical benefits of transarterial chemoembolization combined with tyrosine kinase and immune checkpoint inhibitors for unresectable hepatocellular carcinoma. World J Gastrointest Oncol 2024; 16(7): 3308-3320
URL: https://www.wjgnet.com/1948-5204/full/v16/i7/3308.htm
DOI: https://dx.doi.org/10.4251/wjgo.v16.i7.3308